Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zebularine SCHEMBL12040244 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL12595413 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL13032 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL7122633 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL11910465 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL2563757 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL1649826 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL19656926 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL21842491 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL21474114 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923953-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2020168358-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-20 | — | — | WO | claimed |
| EP-3730139-B1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | WYETH LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | WYETH LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220354820-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | WYETH LLC (US) | 2022-11-10 | — | — | US | disclosed |
| CN-115038466-A | Combination therapy and uses and methods thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3923953-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168358-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2477493-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035019-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354820-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | RICTOR, MTOR, TFPI2 | CDA 4255/4885MAPT 587/4885LMNA 4481/4885 |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | RICTOR, MTOR, TFPI2 | CDA 4255/4885MAPT 587/4885LMNA 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.